Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology

An oral presentation will focus on how compliance and treatment duration may predict survival in newly diagnosed glioblastoma patients treated with Optune® together with temozolomide In total, 54 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts ST. HELIER, …

Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer

The conference is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18thWorld Conference on Lung Cancer, October 15 to October 18 in Yokohama, Japan. “We look forward to …

Novocure to Report Third Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2017 on Thursday, October 26, 2017, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2017, …

Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients

Newly diagnosed glioblastoma patients treated with Optune plus temozolomide were able to maintain quality of life for longer compared to those treated with temozolomide alone Data presented today as a late-breaking oral presentation at the American Society for Radiation Oncology’s 2017 Annual Meeting ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today results from its …

Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting

Late-breaking oral presentation to focus on Optune five-year survival and health-related quality of life data ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today four presentations on Tumor Treating Fields (TTFields) at the American Society for Radiation Oncology’s (ASTRO) 2017 Annual Meeting, September 24 through September 27 in San Diego. A late-breaking oral presentation will focus …

Novocure Announces Data Presentations at the ESMO 2017 Congress

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that four data presentations on Tumor Treating Fields (TTFields) will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, September 8 through September 12 in Madrid, Spain. Among the highlights is a poster discussion of the overall survival and quality of life data …

German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma

Proposed trial design will examine the benefit of combining Optune with radiation therapy and temozolomide prior to the initiation of maintenance temozolomide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, (Gemeinsamer Bundesausschuss or G-BA), has published its decision to support a clinical trial studying Optune for the treatment …

Novocure to Present at Two Upcoming Investor Conferences in September

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in September. William Doyle, Novocure’s Executive Chairman, will participate in the Wells Fargo 2017 Healthcare Conference on September 6, 2017, in Boston. Mr. Doyle’s presentation will begin at 10:15 a.m. EDT and will be followed by a Q&A …

Novocure™ Announces National Reimbursement for Optune® in Austria

The decision marks Novocure’s first national coverage policy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today it has signed a contract with the Federation of the Austrian Social Insurance Institutions which grants reimbursement across Austria for Optune – Novocure’s Tumor Treating Fields (TTFields) delivery system – for the treatment of adults with newly diagnosed …